Galaxy Tab S11 và Tab S11 Ultra ra mắt: Thiết kế siêu mỏng, Samsung Dex cải tiến
Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice:
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) --
The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased shares of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock between October 6, 2020 and October 28, 2022, for violations of the Securities Exchange Act of 1934. Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages. The Company's lead product candidate is Omburtamab. According to Y-mAbs, '131I-omburtamab, which is omburtamab radiolabeled with Iodine-131, is currently being studied in several clinical trials including pivotal stage development Study 101 and Study 03-133 for the treatment of pediatric patients who have CNS/LM from NB.”
What Now: Similarly situated shareholders may be eligible to participate in the class action against Y-mAbs. Shareholders who want to act as lead plaintiff for the class must file their papers by March 20, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
What is this Case аbout: Y-mAbs Therapeutics, Inc. (YMAB) Misrepresented the Viability and Efficacy of its Lead Drug Candidate
According to the complaint, Y-mAbs sought FDA approval of omburtamab through a Biologics License Application first in 2020 and again in 2022, based on a comparison between Study 03-133 performed at Memorial Sloan Kettering Cancer Center (“MSKCC”) and an external cohort comprising data from the Central German Childhood Cancer Registry, or CGCCR, database.
The FDA declined marketing approval of omburtamab in a Refusal to File (RTF) letter dated October 2, 2020, informing Y-mAbs that additional data, including evidence of durable response were necessary to provide the level of evidence needed to support an approval.
Y-mAbs disclosed the existence of the RTF letter in a press release dated October 5, 2020, and in an investor conference call the morning of October 6, 2020, but misrepresented the FDA’s willingness to approve omburtamab for marketing based on the existing clinical trials. In fact, during the class period, Y-mAbs misrepresented to investors that, pursuant to a series of meetings and other communications between Y-mAbs and the FDA, progress was being made that would align with the FDA’s requirement to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies.
To the contrary, the FDA had repeatedly advised the defendants that the FDA was unlikely to grant approval for the marketing of omburtamab based on a comparison between Study 03-133 and CGCCR because of substantial differences in the patient populations, and the absence of tumor response data, and that Study 101 was neither sufficiently advanced nor indicative of efficacy to justify approval. The truth was first disclosed to investors on October 26, 2022, when the FDA published its Briefing Document for an October 28, 2022 Advisory Committee Meeting, and again on October 28, 2022, when the Committee voted 16-0 against recommending approval of omburtamab. On this news, Y-mAbs common shares fell $11.56 per share, to close at $3.61 per share on October 31, 2022.
Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Y-mAbs Therapeutic, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contact: Aaron Dumas Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 adumas@robbinsllp.com (800) 350-6003 www.robbinsllp.com | https://www.facebook.com/RobbinsLLP/ https://www.linkedin.com/company/robbins-llp/ |

TIN LIÊN QUAN
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Y-mAbs
SAN FRANCISCO, March 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses...
Caribou Biosciences, Inc. (CRBU) Shareholder Alert: Robbins
SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons or...
Vertex Energy, Inc. (VTNR) Shareholder Notice: Robbins LLP
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of...
Notice of Filing Securities Class Action Against Global
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. has filed a federal securities class action in the United States District Court...
Beam Therapeutics to Participate in the 43rd Annual Cowen
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...
Lyra Therapeutics Announces Appointment of John Bishop,
WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company...
THỦ THUẬT HAY
Hướng dẫn kích hoạt bảo mật 2 lớp cho Apple ID
Xác thực 2 lớp là tầng bảo mật bổ sung được thiết kế để ngăn chặn truy cập trái phép vào tài khoản của bạn, đồng thời bảo vệ ảnh, tài liệu và các dữ liệu khác được lưu với Apple.
Cách xem tình hình Covid-19 từng tỉnh thành bằng Google Maps đơn giản
Cách xem tình hình Covid-19 từng tỉnh thành bằng Google Maps cực dễ này sẽ giúp bạn dễ dàng nắm được tình hình số liệu ca nhiễm, ca khỏi của các tỉnh thành.
Nạp ga điều hòa, bảng giá, cách nhận biết ga chính hãng
Trong những ngày hè nắng nóng, oi bức thì điều hòa được xem như một trong những thiết bị làm mát hàng đầu, được rất nhiều gia đình lựa chọn sử dụng. Tuy nhiên để sử dụng điều hòa hiệu quả, tiết kiệm điện thì ga điều
Tổng hợp lại cách dùng cũng như các công cụ tạo USB cài Windows
Sau một thời gian sử dụng Windows, chắc hẳn bạn rất muốn cài lại hệ điều hành của mình. Hiện tại có rất nhiều công cụ để tạo USB cài Windows một cách nhanh chóng, và hôm nay TCN sẽ tổng hợp lại cách dùng cũng như các
Thay màn hình iPhone 6s Plus ở đâu chính hãng, giá rẻ
Sử hữu cho mình những chiếc điện thoại smartphone đắt tiền như iPhone 6S Plus luôn là niềm tự hào của nhiều người. Tuy nhiên chằng may chiếc điện thoại iPhone 6S Plus bị rơi vỡ thì việc tìm kiếm thay màn hình iPhone 6s
ĐÁNH GIÁ NHANH
Đánh giá Vivo Y51 – sát thủ phân khúc 3 triệu đồng
Cùng đánh giá Vivo Y51 để xem chiếc smartphone này có xứng đáng là một trong những model smartphone tầm trung đáng sở hữu không nhé!
Mazda CX-8 2018 có thiết kế vận hành và giá bán chính thức thế nào?
Xe Mazda CX-8 2018 có chiều dài 4.900 mm, dài hơn 350 mm so với CX-5, rộng 1.840 mm và cao 1.730 mm. Cả CX-9 và CX-8 đều có cùng chiều dài cơ sở 2.930 mm, tuy nhiên chiều dài cơ học CX-8 ngắn hơn 175 mm và chiều rộng
So sánh Galaxy S10 5G và Mi 11 Lite 5G: Flagship nào đáng mua nhất?
Galaxy S10 5G và Mi 11 Lite 5G là hai thiết bị cùng phân khúc được nhiều người quan tâm, thử mang lên bàn cân xem flagship nào đáng sở hữu nhất.